Pfizer Long Term Debt 2010-2024 | PFE
Pfizer long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- Pfizer long term debt for the quarter ending September 30, 2024 was $58.002B, a 4.99% decline year-over-year.
- Pfizer long term debt for 2023 was $61.538B, a 87.14% increase from 2022.
- Pfizer long term debt for 2022 was $32.884B, a 9.15% decline from 2021.
- Pfizer long term debt for 2021 was $36.195B, a 2.53% decline from 2020.
Pfizer Annual Long Term Debt
(Millions of US $) |
| 2023 |
$61,538 |
| 2022 |
$32,884 |
| 2021 |
$36,195 |
| 2020 |
$37,133 |
| 2019 |
$35,955 |
| 2018 |
$32,909 |
| 2017 |
$33,538 |
| 2016 |
$31,398 |
| 2015 |
$28,740 |
| 2014 |
$31,541 |
| 2013 |
$30,462 |
| 2012 |
$31,036 |
| 2011 |
$34,926 |
| 2010 |
$38,410 |
| 2009 |
$43,193 |
Pfizer Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
$58,002 |
| 2024-06-30 |
$57,506 |
| 2024-03-31 |
$61,307 |
| 2023-12-31 |
$61,538 |
| 2023-09-30 |
$61,048 |
| 2023-06-30 |
$61,356 |
| 2023-03-31 |
$31,704 |
| 2022-12-31 |
$32,884 |
| 2022-09-30 |
$32,629 |
| 2022-06-30 |
$34,294 |
| 2022-03-31 |
$35,656 |
| 2021-12-31 |
$36,195 |
| 2021-09-30 |
$36,250 |
| 2021-06-30 |
$35,354 |
| 2021-03-31 |
$35,347 |
| 2020-12-31 |
$37,133 |
| 2020-09-30 |
$49,785 |
| 2020-06-30 |
$50,529 |
| 2020-03-31 |
$36,281 |
| 2019-12-31 |
$35,955 |
| 2019-09-30 |
$36,044 |
| 2019-06-30 |
$36,168 |
| 2019-03-31 |
$35,733 |
| 2018-12-31 |
$32,909 |
| 2018-09-30 |
$33,652 |
| 2018-06-30 |
$28,935 |
| 2018-03-31 |
$31,831 |
| 2017-12-31 |
$33,538 |
| 2017-09-30 |
$34,503 |
| 2017-06-30 |
$34,191 |
| 2017-03-31 |
$36,330 |
| 2016-12-31 |
$31,398 |
| 2016-09-30 |
$30,437 |
| 2016-06-30 |
$30,457 |
| 2016-03-31 |
$27,824 |
| 2015-12-31 |
$28,740 |
| 2015-09-30 |
$29,079 |
| 2015-06-30 |
$26,729 |
| 2015-03-31 |
$29,370 |
| 2014-12-31 |
$31,541 |
| 2014-09-30 |
$31,666 |
| 2014-06-30 |
$32,267 |
| 2014-03-31 |
$27,649 |
| 2013-12-31 |
$30,462 |
| 2013-09-30 |
$31,812 |
| 2013-06-30 |
$31,532 |
| 2013-03-31 |
$31,481 |
| 2012-12-31 |
$31,036 |
| 2012-09-30 |
$31,083 |
| 2012-06-30 |
$30,868 |
| 2012-03-31 |
$33,543 |
| 2011-12-31 |
$34,926 |
| 2011-09-30 |
$35,399 |
| 2011-06-30 |
$35,723 |
| 2011-03-31 |
$35,308 |
| 2010-12-31 |
$38,410 |
| 2010-09-30 |
$39,010 |
| 2010-06-30 |
$37,765 |
| 2010-03-31 |
$38,281 |
| 2009-12-31 |
$43,193 |
| 2009-09-30 |
$32,402 |
| 2009-06-30 |
$31,864 |
| 2009-03-31 |
$21,064 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
